eyenovia-logo 3

SEC Filings

Form S-1
EYENOVIA, INC. filed this Form S-1 on 12/12/2018
Document Outline
Entire Document (1632.8 KB)
Subdocument 1 - S-1 - FORM S-1
Page 1 - As filed with the Securities and Exchange Commission on December 12, 2018
Page 2 - The information in this preliminary prospectus is not complete and may be changed. We may not sell t
Page 3 - TABLE OF CONTENTS
Page 4 - ABOUT THIS PROSPECTUS
Page 5 - PROSPECTUS SUMMARY
Page 6 - The Optejet
Page 7 - Our Pipeline
Page 8 - Phase III Clinical Development Program
Page 9 - Ophthalmology 2012;119:347 354
Page 10 - Our Strategy
Page 11 - Risks Associated with our Business
Page 12 - Our product candidates are based on a novel technology, which makes it difficult to predict the time
Page 13 - Corporate Information
Page 14 - THE OFFERING
Page 15 - RISK FACTORS
Page 16 - We have not paid dividends in the past and have no immediate plans to pay dividends.
Page 17 - CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 18 - N/A
Page 19 - USE OF PROCEEDS
Page 20 - DILUTION
Page 21 - DESCRIPTION OF SECURITIES
Page 22 - Provisions of our Certificate of Incorporation on Choice of Forum
Page 23 - Delaware Law
Page 24 - UNDERWRITING
Page 25 - Stabilization
Page 26 - Other Relationships with the Underwriter
Page 27 - LEGAL MATTERS
Page 28 - INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
Page 29 - 1,200,000 of Shares of Common Stock
Page 30 - PART II
Page 31 - Item 15. Recent Sales of Unregistered Securities
Page 32 - Item 16. Exhibits and Financial Statement Schedules
Page 33 - SIGNATURES
Page 34 - EXHIBIT INDEX
Subdocument 2 - EX-1.1 - EXHIBIT 1.1
Page 1 - Exhibit 1.1
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - Schedule I
Page 30 - Schedule II
Page 31 - Schedule III
Page 32 - Schedule IV
Page 33 - N/A
Page 34 - Schedule V
Page 35 - Schedule VI
Subdocument 3 - EX-5.1 - EXHIBIT 5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Subdocument 4 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]